

REMARKS

The specification is amended at page 2, line 13 by inserting a reference to Figure 7 and to add an abstract following the claims.

Original claims 1-15 have been canceled without prejudice.

New composition claim 16 corresponds essentially to original claim 11 and new claims 17-25 depend from and further limit the composition of claim 11 in terms of the nature or concentration of its ingredients. The limitation of claims 17-19, and 21-25 correspond to the limitations of the compositions prepared according to original claims 3, 5 and 6-10 respectively, and new claim 20 corresponds to original claim 15.


New claims 26, 27, 29 and 31-35 correspond to original so-called Swiss-type "second indication" claims 1, 3-5 and 6-10 respectively, but written in appropriate U.S. method of treatment format. New claim 30 is directed to the method of using the composition of original claim 15.

New claims 36 and 37 correspond to original claim 3 and 4 insofar as the latter claims depend from claim 2. New claim 38 further defines the cutaneous stress of prior claim 30 as defined in original claim 2. New claims 39-41 correspond to original claims 12-14.

No new matter is added by the amendment of the specification or the addition of new claims 16-41.

Attached hereto is a page entitled "Version With Markings To Show Changes Made" which is a marked-up version of the changes made to the specification and claims by the instant amendment.

Respectfully submitted,



Paul E. Dupont
Reg. No. 27,438

Date: May 14, 2001
 Address:
 Patent Department
 Sanofi-Synthelabo Inc.
 9 Great Valley Parkway
 Malvern, PA 19355
 Telephone No. (610) 889-6338
 Facsimile: (610) 889-8799

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In The Specification:

The paragraph beginning at page 2, line 12 has been amended as follows:

Many PBR ligands are disclosed in the literature (Figure 7). Examples which may be mentioned include Ro 5-4864 or chlorodiazepam, Ro 5-2807 or diazepam and PK 11195, or reference may be made to the article Peripheral Benzodiazepine Receptors, Ch. III, J.J. Bourguignon, Ed. E. Giesen - Crouse, Academic Press.

A new section entitled "Abstract of the Disclosure" has been added at new page 29 immediately following the claims.

In The Claims:

Claims 1-15 have been canceled and new claims 16-41 have been added.

DRAFT - DRAFTING